Stock IVCP SWIFTMERGE ACQUISITION CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News Swiftmerge Acquisition Corp.

Equities

IVCP

KYG638361033

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-02 pm EDT 		5-day change 1st Jan Change
10.77 USD -0.19% Intraday chart for Swiftmerge Acquisition Corp. -0.28% -0.92%
Apr. 01 Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Swiftmerge Acquisition : Non-Reliance on Previously Issued Financial Statements or Related Audit Report or Completed Interim Report - Form 8-K
PU
Swiftmerge Acquisition Signs Merger Deal to Take HDL Therapeutics Public
MT
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
BU
SWIFTMERGE ACQUISITION CORP. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Swiftmerge Acquisition : Adjournment of Extraordinary General Meeting - Form 8-K
PU
Swiftmerge Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
HDL Therapeutics Inc Plans to Become Publicly Traded via a Business Combination With $225 Million Swiftmerge (NASDAQ: IVCP) With Goal to Transform Cardiovascular Disease Treatment
BU
HDL Therapeutics, Inc. signed a non-binding letter of intent to acquire Swiftmerge Acquisition Corp. in a reverse merger transaction.
CI
SWIFTMERGE ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SWIFTMERGE ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Swiftmerge Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Swiftmerge Acquisition Corp. Auditor Raises 'Going Concern' Doubt
CI
Swiftmerge Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SWIFTMERGE ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Swiftmerge Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IVCP Stock
  4. News Swiftmerge Acquisition Corp.